A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
To read the full story
Related Article
- Entyvio Subcutaneous Form Approved in US: Takeda
September 29, 2023
- FDA Accepts for Review Takeda’s Entyvio SC Form for Crohn’s
September 15, 2023
- FDA Accepts BLA Re-Submission for Takeda’s Entyvio SC
May 1, 2023
- US Launch of Takeda’s Entyvio SC to Be Pushed Back to 2022
September 4, 2020
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Entyvio’s SC Form Accepted by US FDA for Review: Takeda
May 13, 2019
BUSINESS
- Chugai Sees 20% of Workforce Apply for Internal Job Postings
July 29, 2025
- Stella to Seek Japan Approval for BNCT as Angiosarcoma Trial Hits Goal
July 29, 2025
- Deciphera’s TGCT Drug Gets Key EMA Backing: Ono
July 29, 2025
- Opdivo-Yervoy Combo Approved for 1st Line HCC in Taiwan
July 29, 2025
- Shionogi, Torii to Start Co-Promotion in September upon Takeover
July 29, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…